drugset / Trial / NCT00745875
ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone
Timeline
- Start
- 2008-08
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zibotentan | Small molecule | 10 mg | Oral |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |